Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes

References

• Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE. 2014. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 36(1):62–70.
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, et al. 2015. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 98(1):19–24.
   PubMed Web of Science ®Google Scholar
• Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, et al. 2019. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 41(3):261–307.
   PubMed Web of Science ®Google Scholar
• Capone D, Tarantino G, Gentile A, Sabbatini M, Polichetti G, Santangelo M, Nappi R, Ciotola A, D'Alessandro V, Renda A, et al. 2010. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther. 35(1):121–124.
   PubMed Web of Science ®Google Scholar
• Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, Wen JQ, Sha GZ, Liu ZH. 2009. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc. 41(5):1557–1561.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang Y, Wang X, Wang C, Lin W, Jiao Z, Wang Z. 2021. Wuzhi capsule dosage affects tacrolimus elimination in adult kidney transplant recipients, as determined by a population pharmacokinetics analysis. Pharmgenomics Pers Med. 14:1093–1106.
   PubMed Web of Science ®Google Scholar
• Cheng F, Li Q, Wang J, Zeng F, Zhang Y. 2021. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients. J Clin Pharm Ther. 46(6):1636–1649.
   PubMed Web of Science ®Google Scholar
• Dashti-Khavidaki S, Ghaffari S, Gohari M, Khatami MR, Zahiri Z. 2016. Tacrolimus dose requirement in iranian kidney transplant recipients within the first three weeks after transplantation. Int J Organ Transplant Med. 7(3):167–171.
   PubMedGoogle Scholar
• De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. 2011. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 67(S1):5–16.
   PubMedGoogle Scholar
• Flahault A, Anglicheau D, Loriot MA, Thervet E, Pallet N. 2017. Clinical impact of the CYP3A5 6986A > G allelic variant on kidney transplantation outcomes. Pharmacogenomics. 18(2):165–173.
   PubMed Web of Science ®Google Scholar
• Fu Q, Jing Y, Liu Mr G, Jiang Mr X, Liu H, Kong Y, Hou X, Cao L, Deng P, Xiao P, et al. 2021. Machine learning-based method for tacrolimus dose predictions in Chinese kidney transplant perioperative patients. J Clin Pharm Ther. DOI:10.1111/jcpt.13579
   Web of Science ®Google Scholar
• Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K, et al. 2001. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 57(6-7):479–484.
   PubMed Web of Science ®Google Scholar
• Golubovic B, Prostran M, Miljkovic B, Vucicevic K, Radivojevic D, Grabnar I. 2016. Population pharmacokinetic approach of immunosuppressive therapy in kidney transplant patients. Curr Med Chem. 23(19):1998–2011.
   PubMed Web of Science ®Google Scholar
• Han N, Yun HY, Hong JY, Kim IW, Ji E, Hong SH, Kim YS, Ha J, Shin WG, Oh JM. 2013. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 69(1):53–63.
   PubMed Web of Science ®Google Scholar
• Israni AK, Riad SM, Leduc R, Oetting WS, Guan W, Schladt D, Matas AJ, Jacobson PA, DeKAF Genomics Investigators. 2013. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. Transpl Int. 26(10):982–989.
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Monma F, Fujieda A, Nakatani K, Gayle AA, Nobori T, Katayama N, Okuda M. 2015. Effect of genetic polymorphism of CYP3A5 and CYP2C19 and concomitant use of voriconazole on blood tacrolimus concentration in patients receiving hematopoietic stem cell transplantation. Therapeutic Drug Monitor. 37(5):581–588.
   PubMed Web of Science ®Google Scholar
• Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. 2001. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant. 28(8):753–758.
   PubMed Web of Science ®Google Scholar
• Jing Y, Kong Y, Hou X, Liu H, Fu Q, Jiao Z, Peng H, Wei X. 2021. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. J Clin Pharm Ther. 46(4):1117–1128.
   PubMed Web of Science ®Google Scholar
• Kim I-W, Moon YJ, Ji E, Kim KI, Han N, Kim SJ, Shin WG, Ha J, Yoon J-H, Lee HS, et al. 2012. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur J Clin Pharmacol. 68(5):657–669.
   PubMed Web of Science ®Google Scholar
• Largeau B, Guellec CB-L, Longuet H, Lesne P, Bouvarel A, Préteseille L, Marquet P, Halimi J-M, Büchler M, Gatault P, et al. 2019. Comparison of tacrolimus starting doses based on CYP3A5 phenotype or genotype in kidney transplant recipients. Prog Transpl. 29(4):300–308.
   PubMed Web of Science ®Google Scholar
• Lee JS, Cheong HS, Kim LH, Kim JO, Seo DW, Kim YH, Chung MW, Han SY, Shin HD. 2013. Screening of genetic polymorphisms of CYP3A4 and CYP3A5 genes. Korean J Physiol Pharmacol. 17(6):479–484.
   PubMed Web of Science ®Google Scholar
• Ling J, Dong LL, Yang XP, Qian Q, Jiang Y, Zou SL, Hu N. 2020. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation. Xenobiotica. 50(12):1501–1509.
   PubMed Web of Science ®Google Scholar
• Liu F, Ou YM, Yu AR, Xiong L, Xin HW. 2017. Long-term influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 polymorphisms on tacrolimus concentration in chinese renal transplant recipients. Genet Test Mol Biomarkers. 21(11):663–673.
   PubMed Web of Science ®Google Scholar
• Liu JC, Gao XL, Jiang TM. 2021. Relationship between CYP3A5 gene polymorphism and concentration/dose of tacrolimus in renal transplant recipients and individualized medication. Chin J Tissue Eng Res. 25(11):1740–1744.
   Google Scholar
• Li SC, Xu H, Ye Q, Wang Y, Wu SL, Cao P. 2020. Population pharmacokinetic model was used to investigate the effect of Wuzhi capsule on the pharmacokinetics of tacrolimus in children with nephrotic syndrome. Chin J New Drugs Clin Remed. 39(8):477–485.
   Google Scholar
• Mi L, Wei H, Li JC, Qin SX, Mao JH. 2016. Effect of Wuzhi capsule on pharmacokinetics of tacrolimus. Med J Chin Peop Arm Pol For. 27(3):240–242.
   Google Scholar
• Mohamed ME, Schladt DP, Guan W, Wu B, Setten J, Keating BJ, Iklé D, Remmel RP, Dorr CR, Mannon RB, The DeKAF Genomics and GEN03 Investigators, et al. 2019. Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: a comparison of four ancestry groups. Am J Transplant. 19(10):2795–2804.
   PubMed Web of Science ®Google Scholar
• Nair SS, Sarasamma S, Gracious N, George J, Anish TSN, Radhakrishnan R. 2015. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Exp Clin Transplant. 13:197–200.
   PubMed Web of Science ®Google Scholar
• Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. 2011. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 72(6):948–957.
   PubMed Web of Science ®Google Scholar
• Peng K, Yang CL, Feng LJ, Xia Q, Xu DJ. 2020. Effects of combined drug use and gene polymorphism on pharmacokinetics of tacrolimus in renal transplant recipients. Central South Pharm. 18(6):963–969.
   Google Scholar
• Pristov KE, Ghannoum MA. 2019. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 25(7):792–798.
   PubMed Web of Science ®Google Scholar
• Reséndiz-Galván JE, Romano-Aguilar M, Medellín-Garibay SE, Milán-Segovia RDC, Niño-Moreno PDC, Jung-Cook H, Chevaile-Ramos JA, Romano-Moreno S. 2020. Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. Eur J Pharm Sci. 150:105370.
   PubMed Web of Science ®Google Scholar
• Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, Oetting WS, Mannon RB, Remmel RP, Matas AJ, et al. 2017. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J. 17(1):61–68.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Willis C, Taylor PJ, Tett SE. 2002. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 72(6):660–669.
   PubMed Web of Science ®Google Scholar
• Stefanovic NZ, Cvetkovic TP, Jevtovic-Stoimenov TM, Ignjatovic AM, Paunovic GJ, Velickovic RM. 2015. Investigation of CYP3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function. Exp Therapeutic Med. 10(3):1149–1156.
   PubMed Web of Science ®Google Scholar
• Shi BY, Ju CHR. 2019. Technical specification for clinical diagnosis and treatment of invasive mycosis in organ transplant recipients (2019 edition). Organ Transplant. 10(03):227–236.
   Google Scholar
• Tang JT, Andrews LM, van Gelder T, Shi YY, van Schaik RHN, Wang LL, Hesselink DA. 2016. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 12(5):555–565.
   PubMed Web of Science ®Google Scholar
• Tian PC, Ao JH, Li N, Shi BY. 2019. Technical specifications for the clinical application of immunosuppressive agents in organ transplantation (2019 edition). Organ Transplant. 10(03):213–226.
   Google Scholar
• Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, et al. 2010. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 87(6):721–726.
   PubMed Web of Science ®Google Scholar
• Togashi M, Niioka T, Komatsuda A, Nara M, Okuyama S, Omokawa A, Abumiya M, Wakui H, Takahashi N, Miura M. 2015. Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. Eur J Clin Pharmacol. 71(9):1091–1097.
   PubMed Web of Science ®Google Scholar
• Xin HW, Li Q, Wu XC, He Y, Yu AR, Xiong L, Xiong Y. 2011. Evaluation of cost and effectiveness of Wuzhi capsule combined with tacrolimus in renal transplant recipients. Chin J Clin Pharmacol. 27(04):295–298.
   Google Scholar
• Yan L, Li Y, Tang JT, An YF, Wang LL, Shi YY. 2016. Donor ABCB1 3435 C > T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. Pharmacogenomics. 17(3):249–257.
   PubMed Web of Science ®Google Scholar
• Yan L, Yang ZQ, Shi YY, Ren J, Yang CL, Wan ZL, Bai YJ, Luo LM, Wang LL, Li Y. 2019. Effects of Wuzhi capsules on blood concentration of tacrolimus in renal transplant recipients. Ann Transplant. 24:594–604.
   PubMed Web of Science ®Google Scholar
• Yoo HH, Lee M, Lee MW, Lim SY, Shin J, Kim DH. 2007. Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2. Planta Med. 73(5):444–450.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Zhang H, Ding XL, Ma S, Miao LY. 2013. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur J Clin Pharmacol. 69(4):807–812.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Liu SB, Xue L, Ding XL, Zhang H, Miao LY. 2015. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. CP. 53(09):728–736.
   Google Scholar
• Zhang Z, Lu X, Dong L, Ma J, Fan X. 2019. Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients. Medicine (Baltimore). 98(48):e18150.
   PubMed Web of Science ®Google Scholar
• Zhao CY, Jiao Z, Mao JJ, Qiu XY. 2016. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 81(5):891–907.
   PubMed Web of Science ®Google Scholar